Xiang-Yi Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiang-Yi Li has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Junqing Zhang
Hainan Provincial Key Laboratory of Research and Development of Tropical Medicinal Plants, Hainan Medical University, Haikou 571199, China
2 shared publications Ai-Xia Liu
Key Laboratory of Tropical Translational Medicine of Ministry of Education, Hainan Provincial Key Laboratory for Research and Development of Tropical Herbs, Haikou Key Laboratory of Li Nationality Medicine, School of Pharmacy, Hainan Medical University, Haikou, 571199, China
1 shared publication- Feihu Bai
Department of Gastroenterology, The Second Affiliated Hospital of Hainan Medical University, Haikou, China
1 shared publication Hailong Li
Hainan Provincial Key Laboratory for Research and Development of Tropical Herbs, Haikou Key Laboratory of Li Nationality Medicine, School of Pharmacy, Hainan Medical University, Haikou, China
1 shared publication- Jian Xu
Center for Craniofacial Molecular Biology, Department of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California
1 shared publication - Minghai Fu
Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, Hainan Provincial Key Laboratory for Research and Development of Tropical Herbs, School of Pharmacy, Hainan Medical University, Haikou 571199, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2023 (1) , 4934711
Investigation of the Potential Mechanism of Alpinia officinarum Hance in Improving Type 2 Diabetes Mellitus Based on Network Pharmacology and Molecular Docking
Objective. We used network pharmacology, molecular docking, and cellular analysis to explore the pharmacodynamic components and action mechanism of Alpinia officinarum Hance (A. officinarum) in improving type 2 diabetes mellitus (T2DM). Methods. The protein‐protein interaction (PPI) network, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to predict the potential targets and mechanism of A. officinarum toward improving T2DM. The first 9 core targets and potential active compounds were docked using Discovery Studio 2019. Finally, IR‐HepG2 cells and qPCR were applied to determine the mRNA expression of the top 6 core targets of the PPI network. Results. A total of 29 active ingredients and 607 targets of A. officinarum were obtained. T2DM‐related targets overlapped with 176 targets. The core targets of the PPI network were identified as AKT serine/threonine kinase 1 (AKT1), an activator of transcription 3 (STAT3), tumor necrosis factor (TNF), tumor protein p53 (TP53), SRC proto‐oncogene, nonreceptor tyrosine kinase (SRC), epidermal growth factor receptor (EGFR), albumin (ALB), mitogen‐activated protein kinase 1 (MAPK1), and peroxisome proliferator‐activated receptor gamma (PPARG). A. officinarum performs an antidiabetic role via the AGE‐RAGE signaling pathway, the HIF‐1 signaling pathway, the PI3K‐AKT signaling pathway, and others, according to GO and KEGG enrichment analyses. Molecular docking revealed that the binding ability of diarylheptanoid active components in A. officinarum to core target protein was higher than that of flavonoids. The cell experiments confirmed that the A. officinarum extracts improved the glucose uptake of IR‐HepG2 cells and AKT expression while inhibiting the STAT3, TNF, TP53, SRC, and EGFR mRNA expression. Conclusion. A. officinarum Hance improves T2DM by acting on numerous components, multiple targets, and several pathways. Our results lay the groundwork for the subsequent research and broaden the clinical application of A. officinarum Hance.
- 1 January 2023
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2023 (1) , 4934711
Open AccessInvestigation of the Potential Mechanism of Alpinia officinarum Hance in Improving Type 2 Diabetes Mellitus Based on Network Pharmacology and Molecular Docking
Objective. We used network pharmacology, molecular docking, and cellular analysis to explore the pharmacodynamic components and action mechanism of Alpinia officinarum Hance (A. officinarum) in improving type 2 diabetes mellitus (T2DM). Methods. The protein‐protein interaction (PPI) network, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to predict the potential targets and mechanism of A. officinarum toward improving T2DM. The first 9 core targets and potential active compounds were docked using Discovery Studio 2019. Finally, IR‐HepG2 cells and qPCR were applied to determine the mRNA expression of the top 6 core targets of the PPI network. Results. A total of 29 active ingredients and 607 targets of A. officinarum were obtained. T2DM‐related targets overlapped with 176 targets. The core targets of the PPI network were identified as AKT serine/threonine kinase 1 (AKT1), an activator of transcription 3 (STAT3), tumor necrosis factor (TNF), tumor protein p53 (TP53), SRC proto‐oncogene, nonreceptor tyrosine kinase (SRC), epidermal growth factor receptor (EGFR), albumin (ALB), mitogen‐activated protein kinase 1 (MAPK1), and peroxisome proliferator‐activated receptor gamma (PPARG). A. officinarum performs an antidiabetic role via the AGE‐RAGE signaling pathway, the HIF‐1 signaling pathway, the PI3K‐AKT signaling pathway, and others, according to GO and KEGG enrichment analyses. Molecular docking revealed that the binding ability of diarylheptanoid active components in A. officinarum to core target protein was higher than that of flavonoids. The cell experiments confirmed that the A. officinarum extracts improved the glucose uptake of IR‐HepG2 cells and AKT expression while inhibiting the STAT3, TNF, TP53, SRC, and EGFR mRNA expression. Conclusion. A. officinarum Hance improves T2DM by acting on numerous components, multiple targets, and several pathways. Our results lay the groundwork for the subsequent research and broaden the clinical application of A. officinarum Hance.